title: A preliminary evaluation of the efficacy and safety of Cogent db (an ayurvedic drug) in the glycemic control of patients with type 2-diabetes.
abstract: OBJECTIVE
  A nonrandomized, non-placebo-controlled clinical trial to evaluate the efficacy of Cogent db (an herbal preparation; Cybele Herbal Laboratories [PVT] Ltd. Kochi, Kerala State, India) as an adjuvant in the treatment of patients with type 2 diabetes was carried out during a 3-month period.
  
  
  METHODS
  This study was conducted in two major peripheral clinics of Kuala Lumpur in the Klang Valley, Malaysia.
  
  
  METHODS
  A total of 39 Cogent db-treated cases and 40 age-matched controls were recruited for this preliminary study. Nineteen (19) subjects (10 and 9 from control and treatment groups, respectively) dropped out of the study leaving a total of 60 subjects (30 each for control and treatment groups) who completed the study.
  
  
  METHODS
  All subjects in the treatment group were given Cogent db (2 tablets three times daily after each meal) in addition to the regular allopathic drugs (Daonil, [Aventis Farma, SA Petaling Jaya, Selangor State, Malaysia] and Diamicron [Sevier, Bangkok, Thailand], with or without Metformin [Upha Corporation, Bangi, Selangor State, India]) that they took in common with the control group.
  
  
  METHODS
  Thirty-two (32) clinical variables were investigated, including liver enzymes, kidney function tests, hematologic parameters, blood glucose, insulin, and C-peptide assays.
  
  
  RESULTS
  At the end of 3 months it was found that there was a significant decrease in the levels of fasting and postprandial blood glucose, cholesterol, triglycerides, glycated hemoglobin (Hb A(1C)) and fasting insulin in the treatment group compared to the controls. Cogent db did not alter the liver function tests, hematologic parameters, or the kidney function tests.
  
  
  CONCLUSIONS
  These results concur with earlier animal studies that indicate that Cogent db is safe, reliable, tolerable, and efficacious in the control of type 2 diabetes mellitus.
authors.affiliation: Oze's Ayurvedic Medical Centre, Kuala Lumpur, Malaysia.
authors.forename: K Chandra
authors.initials: KC
authors.lastname: Shekhar
authors.forename: Francis I
authors.initials: FI
authors.lastname: Achike
authors.forename: Gurpreet
authors.initials: G
authors.lastname: Kaur
authors.forename: Prem
authors.initials: P
authors.lastname: Kumar
authors.forename: Rohaini
authors.initials: R
authors.lastname: Hashim
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects*; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects; D006456:Hemoglobinuria; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008296:Malaysia; D008297:Male; D008515:Medicine, Ayurvedic; D008875:Middle Aged; D028321:Plant Preparations; D012720:Severity of Illness Index; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D002784:Cholesterol; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D028321:Plant Preparations; D014280:Triglycerides; C450063:cogent db